Physician profile
Timothy Smith
NPI 1306094198
$19,205.73
in general payments reported to CMS, 2019-2025
21 companies · $5,974 in 2025
The $5,974 reported for 2025 was more than what 98% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,794 · 2022: $2,347 · 2023: $2,692 · 2024: $6,398 · 2025: $5,974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $2,251 · Education: $396 · Travel and Lodging: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,278.03 |
| Consulting Fee | $2,250.50 |
| Education | $395.89 |
| Travel and Lodging | $140.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,872.71 | 2021-2025 | |
| Janssen Biotech, INC. | $2,650.85 | 2021-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $2,115.37 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,930.25 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $1,777.16 | 2021-2025 | Dupixent |
| Ucb, INC. | $1,512.72 | 2021-2025 | Bimzelx |
| Dermavant Sciences, INC. | $1,051.91 | 2022-2024 | Vtama |
| Genzyme Corporation | $955.91 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $896.76 | 2021-2025 | Ilumya |
| Galderma Laboratories, L.P. | $726.94 | 2021-2025 | Nemluvio, Aklief |
| Incyte Corporation | $543.61 | 2021-2025 | Opzelura, Opzelura |
| Pfizer INC. | $515.48 | 2021-2025 | |
| Lilly USA, LLC | $453.38 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Arcutis Biotherapeutics, INC. | $331.24 | 2024-2025 | Zoryve |
| Organon LLC | $327.41 | 2025 | Vtama |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $268.40 | 2024-2025 | Tremfya |
| Orthofix Medical, INC. | $132.21 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.84 | 2024 | Spevigo |
| Amgen INC. | $44.69 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.37 | 2021 | |
| Leo Pharma INC. | $13.52 | 2025 | Adbry |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.